Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles

BACKGROUND: Pancreatic ductal adenocarcinoma (PDA) remains the most aggressive cancers with a 5-year survival below 10%. Systemic delivery of chemotherapy drugs has severe side effects in patients with PDA and does not significantly improve overall survival rate. It is highly desirable to advance th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shu-ta, Fowler, Anthony J., Garmon, Corey B., Fessler, Adam B., Ogle, Joshua D., Grover, Kajal R., Allen, Bailey C., Williams, Chandra D., Zhou, Ru, Yazdanifar, Mahboubeh, Ogle, Craig A., Mukherjee, Pinku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914049/
https://www.ncbi.nlm.nih.gov/pubmed/29685122
http://dx.doi.org/10.1186/s12885-018-4393-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914049/
https://www.ncbi.nlm.nih.gov/pubmed/29685122
http://dx.doi.org/10.1186/s12885-018-4393-7

Ejemplares similares